RemeGen Co. Ltd. recently gave an oral presentation on an interim analysis of the evaluation of the Company’s proprietary Disitamab Vedotin, an investigational anti-HER2 antibody-drug conjugate targeting prevalent solid tumor cancers with significant unmet medical needs, at the European Congress on Gynaecological Oncology held in Barcelona from March 7-10, 2024.
